Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates insulin biosynthesis and secretion in a glucose-dependent manner and has been reported to induce vasodilatation. Here, we examined the possible vasorelaxant effect of GLP-1 and its underlying mechanisms.
Introduction
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone secreted in response to nutrient ingestion. GLP-1 has a blood glucose-lowering effect by stimulating an increase in insulin biosynthesis and secretion and by inhibiting glucagon secretion in a glucose-dependent manner. Moreover, GLP-1 inhibits gastric emptying, augments satiety and promotes weight loss (Holst, 2004; Davies et al., 2015) . Growing evidence suggests that it may also play a role in the regulation of cardiovascular function (Drucker, 2016) . The GLP-1 analogue liraglutide is approved for the treatment of Type 2 diabetes mellitus (T2D) and obesity (Ussher and Drucker, 2014; EMA, 2017) and decreased BP and the risk of cardiovascular events (Fonseca et al., 2014; Gejl et al., 2015; Marso et al., 2016; Starup-Linde et al., 2014) . GLP-1 and liraglutide bind to the GLP-1 receptor, a GPCR (Ussher and Drucker, 2014; Alexander et al., 2017a) . In the cardiovascular system, the GLP-1 receptor is expressed in smooth muscle cells, the sinoatrial node (Pyke et al., 2014) , the myocardium and microvascular endothelium (Ban et al., 2008; Bhashyam et al., 2010) . However, some papers have questioned data obtained using standard antisera to detect GLP-1 receptors (Pyke and Knudsen, 2013; Panjwani et al., 2012) .
Agonists of GLP-1 receptors induce vasodilatation, increase blood flow and improve vascular endothelial function (Drucker, 2016; Gejl et al., 2012) , but the results of studies in isolated arteries are conflicting. Generally, it has been assumed that the vasodilatory actions of GLP-1 are dependent on GLP-1 receptors, but some studies proposed vascular effects independent of these receptors (Ban et al., 2008) . It has also been questioned whether the cleaved metabolite, GLP-1(9-36), of native GLP-1(7-36) plays a role (Bayram et al., 2014; Ban et al., 2008) . Several pathways have been suggested to mediate the vascular effects of GLP-1 receptor agonists. These include direct effect on the smooth muscle cells, endothelium-dependent release of NO (Nystrom et al., 2005) and pathways involving an increase in cGMP or cAMP as well as protection against endothelial dysfunction (Ban et al., 2008; Green et al., 2008; Bayram et al., 2014; Koska et al., 2015; Salheen et al., 2015) . However, an indirect vasoconstricting effect of GLP-1 causing inhibition of relaxations induced by VEGF has also been described in mesenteric arteries and was associated with a decrease in endothelial cell calcium (Egholm et al., 2016) . Therefore, the effect on vascular tone of GLP-1 is unclear, and a possible effect of GLP-1 on the peripheral autonomic nervous system has not been examined despite the fact that several other gut-derived peptides regulate the release of noradrenaline in the vasculature (Gradin et al., 2006) . Moreover, hyperglycaemia generates ROS which have been proposed to impair endotheliumdependent relaxation, and growing evidence reveals that GLP-1 receptor stimulation may reduce ROS (Salheen et al., 2015; Steven et al., 2017) and hence improve endothelial function (Salheen et al., 2015) .
In the present study, we aimed to examine the prejunctional and post-junctional vasorelaxant effects of native GLP-1(7-36), liraglutide and GLP-1(9-36) in rat and human resistance vessels, in order to elucidate the signalling pathways involved in GLP-1-mediated regulation of vascular tone. We hypothesized that stimulation of GLP-1 receptors regulates vascular tone by direct effects on signalling pathways determining the contractile level of the smooth muscle cells, by an endothelium-dependent pathway or by inhibition of noradrenaline release from nerves in the vascular wall during conditions with increased sympathetic nerve activity. Moreover, we aimed to investigate whether GLP-1, by inhibition of superoxide production, may improve ACh relaxations in rat mesenteric arteries exposed to hyperglycaemic conditions.
Methods

Tissue preparations
All animal care and experimental procedures were conducted in accordance with the Danish legislation of animal use for scientific procedures and approved by the Danish Experimental Animal Inspectorate (permission 2014-15-2934-01059), according to the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Adult male Wistar rats (10-12-weeks old) of the Hannover strain (RGD Cat# 1566433, RRID:RGD_1566433) and weighing 300-350 g were obtained from either Taconic, Ry, Denmark, or Janvier Laboratories, France. The rats were housed in cages (Techniplast, Buguggiate, Italy, 800 cm 2 ) filled with aspen woodchips (Tapvei, Datesand, Manchester, UK) and nesting material (Soft Paper Wool/LBS, UK) as bedding and under constant climatic conditions (20°C, 60% humidity, 12:12 h light-dark cycle). The animals had access to food (Altromin 1324, Brogaarden ApS, Denmark) and water ad libitum. The animals were selected randomly, and, wherever possible, observations were made without knowledge of the treatments administered. The rats were killed by a blow to the head followed by exsanguination. The mesenteric bed was removed, and it was immediately placed in cold physiological salt solution (PSS) (4°C) of the following composition (mM): NaCl 119, KCl 4.7, KH 2 PO 4 1.18, MgSO 4 1.17, NaHCO 3 25, CaCl 2 1.6, EDTA 0.026 and glucose 5.5. The solution was gassed with 5% CO 2 in air to maintain the pH at 7.4. Third-order mesenteric arteries (internal diameter ≈ 200-300 μm) were dissected without branches (straight segments) or with at least one major branch (branched vessels).
The study using human arterial tissue was approved by the Regional Ethics Committee, Central Denmark (permission number: 1-10-72-208-15) and conducted in accordance with the principles of the Helsinki Declaration II for medical research. All participants gave informed consent prior to participation. To be included in the study, the patients had to be (i) adult competent persons, (ii) Caucasians and (iii) diagnosed with peripheral arterial disease or ischaemic heart disease. Both diabetic and non-diabetic patients were included. The patients were excluded if they were currently treated with GLP-1 analogues. Human arteries were obtained from the Department of Vascular Surgery, Aalborg University Hospital. Subcutaneous tissue samples were obtained from 23 patients undergoing vascular surgery, and they were placed in cold PSS immediately after extraction. Subcutaneous arteries with internal diameters ≈ 200-400 μm were dissected.
Isometric tension recordings
Arterial segments (approximately 2 mm long) were mounted on two wires (40 μm in diameter) in microvascular myographs (Danish Myotechnology, Aarhus, Denmark) for isometric tension recordings. The vessels were equilibrated in oxygenated (5% CO 2 in air) PSS (pH 7.4) heated to 37°C. To determine the lumen diameter that the artery would have had in vivo when relaxed and under a transmural pressure of 100 mmHg, the vessels were stretched following a standardized procedure. Arteries were set to 90% of this diameter, which is the optimal vessel circumference for maximal force development (Mulvany and Halpern, 1977) . To test tissue viability, arterial segments were subjected to an isotonic PSS containing a high concentration of potassium (123 mM) or noradrenaline (1-10 μM) resulting in maximal contraction of the vessels. To test endothelial function, the vessels were contracted with phenylephrine or noradrenaline and then stimulated with ACh (10 μM) in rat arteries and with bradykinin (30 nM) in human arteries. Only rat mesenteric arteries relaxing more than 75% to ACh and human s.c. arteries relaxing more than 50% to bradykinin were included in the study.
The possible direct effect of GLP-1 and analogues in rat and human resistance arteries was examined by adding increasing cumulative concentrations of GLP-1(7-36), liraglutide or GLP-1(9-36) (0.1 pM-100 nM) to vessels contracted with phenylephrine (5-10 μM). To address the potential development of tachyphylaxis, a single physiological concentration of GLP-1(7-36) (1 nM) was added in a series of experiments. To investigate whether GLP-1 was degraded, preparations were incubated with a dipeptidyl peptidase 4 (DPP-4) inhibitor, linagliptin (10 À6 M), before adding GLP-1. All treated vessels were compared with control vessels contracted with phenylephrine alone and assessed at the same time.
To consider whether the vasoregulatory effect of GLP-1 is endothelium dependent, we measured the effects of incubation with therapeutic concentrations (10 nM) of GLP-1(7-36), liraglutide and GLP-1(9-36) for 20 min before adding increasing cumulative concentrations of ACh (0.1 nM-10 μM) to rat mesenteric arteries contracted with phenylephrine (10 μM). The experiments were performed at a low glucose concentration of 5.5 mM and at a very high glucose concentration, as a model of hyperglycaemia. In the hyperglycaemic condition, the vessels were incubated for at least 2 h with 40 mM of glucose before running the protocol, as described by Salheen et al. (2015) . The very high concentration of glucose was based on findings in previous studies, demonstrating that incubation with a similar high glucose concentration (44 mM) for a short time (4-6 h) impaired endothelium-dependent relaxation in isolated vessels (Tesfamariam et al., 1991; Qian et al., 2006) . The responses were examined during co-incubation with the GLP-1 receptor antagonist exendin-(9-39) (100 nM). Similar experiments were performed in human s.c. arteries. Concentration-response curves for another endotheliumdependent relaxant, bradykinin (0.1 pM-100 nM), was obtained in human arteries contracted with phenylephrine (5 μM) and preincubated with therapeutic concentrations (10 nM) of GLP-1(7-36) and liraglutide. Furthermore, human arteries were incubated with a combination of GLP-1(7-36) and exendin-(9-39) (100 nM) to examine whether the effect of GLP-1 is mediated through GLP-1 receptors. In all the experiments, equivalent solvent concentrations (vehicle) were added to a control vessel assayed in parallel, as a time control.
To investigate the role of superoxide in the inhibition of ACh relaxations in high glucose, mesenteric arteries exposed to 40 mM for 2 h of glucose were incubated with vehicle or the SOD scavenger, tempol (10 À4 M), and a concentration-response curve was constructed for ACh. To clarify whether the GLP-1-receptor-independent effect of GLP-1 on ACh relaxation in high glucose is due to an antioxidant effect of GLP-1, rat mesenteric arteries were incubated with indomethacin (10 À6 M) and the superoxide generator pyrogallol (30 μM) for 30 min, phenylephrine was added and the preparations were incubated with vehicle, GLP-1 (10 À8 M), liraglutide (10 À8 M), tempol (10 À4 M) or linagliptin (10 À6 M). Finally, concentration-response curves were constructed for ACh.
Detection of vascular superoxide anions
The levels of vascular superoxide anions were measured using the oxidative fluorescent dye dihydroethidium (Cat# D1137, Invitrogen, Thermo Fisher Scientific, Denmark) (Symons et al., 2006; Christensen et al., 2007) . Freshly dissected mesenteric arteries were placed in PSS (see composition above) in Eppendorf vials at 37°C. They were kept in normoglycaemic conditions (5.5 mM glucose) or in high glucose (40 mM) for 2.5 h, and those with high glucose during the last 30 min were incubated with vehicle, polyethylene glycol superoxide dismutase (PEG-SOD, 900 U·mL À1 ), GLP-1 (10 À8 M), liraglutide (10 À8 M) or linagliptin (10 À6 M). All segments were incubated with dihydroethidium (4 μM) or with PBS (vehicle/time control) at 37°C in light-protected vials, rinsed once with 400 μL to PBS to remove non-oxidized dihydroethidium and mounted on slides with the mounting medium Vectashield (Vector Laboratories, Inc., Burlingame, CA, USA). O 2 À production was estimated using fluorescence microscopy (Leica, Mannheim, Germany) with an ethidium bromide excitation, 488 nm; ethidium bromide emission, 580 to 630 nm band-pass filter. Fluorescence measurements were performed, and the vascular area measured was calculated on the basis of white light pictures. Identical settings were used for all vascular segments and pictures. Relative fluorescence intensity was measured using the image analysis software (Fiji, RRID:SCR_002285) (Schindelin et al., 2012) . The data are reported as PEG-SOD sensitive fluorescence.
Electrical field stimulation
Electrical field stimulation (EFS) was performed as previously described (Simonsen et al., 2008) . Platinum electrodes (2 × 2 mm) secured in plastic mounting heads were placed on either side of the vessel approximately 1 mm from the vessel wall. The electrodes were connected to an electrical stimulator with a constant current output (CS200; Danish Myotechnology). EFS (16 Hz, 0.3 ms pulses, 10 s trains, 40 mA) was applied every 5 min. Increasing cumulative concentrations of GLP-1(7-36) and liraglutide (0.1-300 nM) were added 3 min before each stimulation. The contractile responses were expressed relative to an average of two initial control stimulations and compared with a parallel running time control. To obtain reproducible contractions, propranolol (1 μM), a β-adrenoceptor antagonist, and cocaine (1 μM), an inhibitor of neuronal noradrenaline reuptake, were added. The vessels were also stimulated in the presence of tetrodotoxin, a blocker of the voltage-gated sodium channels in nerve cell membranes.
Data calculations and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . In view of previous experience, each group had to contain preparations from a minimum of 5-6 different subjects. Relaxation and contractile responses in the arteries were measured as the force ΔF (mN) developed by the artery and illustrated the changes in active wall tension. Relaxation in contracted arteries was presented as percentage of the contraction level just before adding the relaxing agents. Differences in concentration-response relationships between treatments were analysed using two-way ANOVA followed by Bonferroni corrections. The fluorescence results for vascular superoxide were compared using one-way ANOVA followed by Tukey's multiple comparisons test. Comparison of ÀlogEC 50 values was analysed with a t-test. Results were considered statistically significant at P < 0.05. GraphPad Prism 7 (GraphPad Prism, RRID: SCR_002798, Inc., San Diego, CA, USA) was used for the statistical analysis.
Materials
ACh, bradykinin, linagliptin, noradrenaline hydrochloride, phenylephrine, propranolol, cocaine, tempol and GLP-1 amide fragment 7-36 (human) were all purchased from Sigma-Aldrich (St Louis, MO, USA). GLP-1(7-36) amide (human and rat), GLP-1(9-36) amide and exendin-3(9-39) amide were from Tocris Bioscience (Bristol, UK). Tetrodotoxin from BioNordika (Herlev, Denmark). All chemicals were dissolved in distilled water except for GLP-1(7-36) human (1% acetic acid). Victoza injection liquid (liraglutide) from Novo Nordisk (Copenhagen, Denmark) was diluted in bubbled PSS, without Ca ++ , at 37°C.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Direct effect of GLP-1 receptor agonists on smooth muscle cell relaxation
In straight rat and human resistance arteries contracted with phenylephrine, native GLP-1 failed to cause relaxation. When adding a single physiological concentration of GLP-1 (1 nM) to the contracted vessels, the observed response was similar to the loss of tone in the parallel running time control ( Figure 1A ,B and Supporting Information Figure S1 ). Concentration-response curves in both rat mesenteric arteries and human s.c. arteries showed no or only a very modest effect, as the observed GLP-1-mediated relaxation was close to 0% ( Figure 1C,D) . Incubation with a DPP-4 inhibitor, linagliptin (10 À6 M), did not cause relaxation or increase the response to GLP-1 (Supporting Information Figure S1 ). Likewise, no vasorelaxant effect was found for native GLP-1 or GLP-1(9-36) in branched mesenteric arteries (Figure 2A,B) . Whereas liraglutide induced significant relaxation compared with vehicle, to approximately 40% of maximal relaxation, as demonstrated on the concentration-response curve in branched mesenteric arteries ( Figure 2C ). This effect was antagonized by adding of the GLP-1 receptor antagonist exendin(9-39) ( Figure 2D ).
Effect of GLP-1 receptor agonists on the EFS-evoked contractions
To examine the potential influence of GLP-1 on the sympathetic nerves in the vascular wall, the vessels were contracted by EFS. Representative traces from the EFS experiments illustrate the lack of inhibitory effect of GLP-1 and liraglutide on the responses to EFS ( Figure 3A and Supporting Information Figure S2 ), indicating that GLP-1
Differing effects of GLP-1 and liraglutide on vascular tone and liraglutide have no effect on the neurotransmitter release from the nerves in the vascular wall. GLP-1 and liraglutide did not have any significant effect on either the amplitude of the contractions or the area under curve (AUC, Figure 3B ,C). Tetrodotoxin, a blocker of the voltage-gated sodium channels in nerve cell membranes, inhibited the EFS-evoked contractions. This ensured that the contractions examined here were due to stimulation of the nerves and not to a direct effect on the smooth muscle cells.
Effect of GLP-1 and liraglutide on endothelium-dependent relaxation in human subcutaneous arteries
In human s.c. vessels from patients with peripheral arterial disease (Table 1) , GLP-1 (10 À8 M) leftward-shifted concentration relaxation curves for the endothelium-dependent vasodilator, bradykinin ( Figure 4A ). Incubation with liraglutide (10 À8 M) failed to change the concentration-response curves for bradykinin in human s.c. arteries ( Figure 4B ). Vessels were obtained from patients diagnosed without diabetes (nondiabetics; n = 6) and with diabetes (diabetic patients; n = 4). GLP-1 also leftward-shifted the concentrationresponse curves for bradykinin in s.c. vessels from nondiabetic patients (n = 6), while the effect was not apparent in s.c. arteries from patients with diabetes (n = 4; Supporting Information Figure S3 ). In a pooled sample of arteries from patients with and without diabetes, GLP-1 still leftward-shifted the concentration-response curves for bradykinin in the presence of the GLP-1 receptor antagonist exendin(9-39) (n = 5, Figure 4C ).
Effect of GLP-1 and liraglutide on endothelium-dependent relaxation in rat mesenteric small arteries At a normoglycaemic condition of 5.5 mM glucose, GLP-1 did not change the relaxation to ACh in rat mesenteric arteries (Supporting Information Figure S4 ). In the first set of experiments with the model of hyperglycaemia, incubation of rat mesenteric vessels with 40 mM of glucose significantly impaired the relaxant response to ACh ( Figure 5A ). Based on these findings and to ensure that only vessels that had actually been affected by the hyperglycaemic condition were included in the GLP-1 study, experiment with a 40 mM glucose control vessel that relaxed more than 40% at 30 nM ACh was excluded (n = 6). GLP-1 significantly improved the relaxation to increasing concentrations of ACh at a high glucose concentration ( Figure 5B ). The response to ACh at high glucose in the presence of GLP-1 was similar to the response to ACh at a low glucose concentration. Exendin(9-39) did not block this effect ( Figure 5C ). The GLP-1 potentiation of ACh-induced relaxation was examined at GLP-1 concentrations of 0.1-10 nM, though only 10 nM GLP-1 significantly improved ACh potency (Supporting Information Figure S4 ). The GLP-1 analogue, liraglutide, and the metabolite of GLP-1, GLP-1(9-36), failed to change ACh-induced relaxations ( Figure 5D ,E). Incubation with the superoxide scavenger, tempol (10 À4 M), leftwardshifted the concentration-response curves for ACh in mesenteric arteries exposed to high glucose ( Figure 5F ).
Effect of GLP-1 and liraglutide on vascular superoxide levels
To investigate the role of superoxide in the effects of GLP-1, rat mesenteric arteries were exposed to the superoxide generator pyrogallol in the absence and the presence of GLP-1 and liraglutide. In the presence of pyrogallol, concentration-response curves for ACh were leftwardshifted after incubation with GLP-1 ( Figure 6A ), while the presence of liraglutide failed to change the curves for ACh in arteries exposed to pyrogallol ( Figure 6B ). To directly measure vascular superoxide levels, the preparations were stained with dihydroethidium ( Figure 7A,F) . The changes in fluorescence were expressed relative to the effect of the superoxide scavenger, PEG-SOD ( Figure 7G ). Incubation with high glucose (40 mM) markedly increased the vascular superoxide levels compared with vessels kept at 5 mM glucose. GLP-1 decreased the superoxide Vasodilatation induced by liraglutide in rat mesenteric arteries with branches. Concentration-response curves for (A) native GLP-1 (n = 6) and vehicle (n = 6), (B) GLP-1(9-36) (n = 6) and vehicle (n = 6), (C) liraglutide (n = 6) and vehicle (n = 6) and (D) liraglutide (n = 6) and liraglutide plus exendin(9-39) (n = 6). The results are means ± SEM. *P < 0.05, significantly different as indicated; two-way ANOVA. levels in vascular preparations exposed to high glucose, while the effect was less pronounced for liraglutide and linagliptin ( Figure 7G ).
Discussion
The present study demonstrates that liraglutide induces vasorelaxation in branched rat mesenteric arteries, whereas no direct vasodilating effect and no effect on the sympathetic nerves in the vascular wall of native GLP-1, GLP-1(9-36) or liraglutide, was found in resistance arteries without branches. In contrast to liraglutide, GLP-1 leftward-shifted the concentration relaxation curves for bradykinin in s.c. arteries from patients with peripheral arterial disease, an effect resistant to exendin(9-39). This study also suggests that, at a high glucose concentration, native GLP-1, by a GLP-1 receptorindependent mechanism, may potentiate ACh relaxation in small rat mesenteric arteries by decreasing vascular superoxide levels. 
The direct GLP-1 effect
Previous studies have suggested a direct vasodilating effect of GLP-1 in isolated mesenteric arteries from rodents and of GLP-1 receptor agonists in human s.c. arteries, as an explanation of the BP-lowering effect observed in patients treated with GLP-1 receptor agonists (Ban et al., 2008; Bayram et al., 2014; Koska et al., 2015) . These studies show an effect at GLP-1 receptors of agonist concentrations varying from 3 pM to 3 nM. We did not find any direct vasodilating effect in human or rat resistance arteries without branches at similar GLP-1 concentrations. In our experiments, GLP-1 failed to cause a relaxing response that was any different from the changes in artery tone in our time controls. Neither did we find any vasoconstricting effect of GLP-1 in mesenteric arteries, as has been suggested in a previous in vivo study in rats (Gardiner et al., 2006) . None of the studies that found a direct vasodilating effect of GLP-1 describe or show a time-control response. Therefore, it is unclear if they have actually considered the changes in artery tone due to time, as an explanation of the observed GLP-1-induced vasodilatation. Contrary to the findings in vessels without branches, we did observe a direct vasorelaxant effect of liraglutide in branched rat mesenteric arteries that was inhibited by the GLP-1 receptor antagonist, exendin(9-39). This finding suggests a GLP-1 receptor-dependent and consequently exendin(9-39)-sensitive mechanism, consistent with the fact that liraglutide is a selective GLP-1 receptor agonist. A more pronounced expression of GLP-1 receptors at branching points in the vascular bed may explain this effect. GLP-1 receptors are expressed in small arteries of the intestine, colocalized with smooth muscle α-actin (Richards et al., 2014) , supporting the findings of a direct effect of liraglutide in mesenteric branched resistance arteries. Whether the expression of GLP-1 receptors is concentrated around branching points remains to be examined in future studies. Both native GLP-1(7-36) and the metabolite GLP-1(9-36) did not evoke a similar response in branched rat mesenteric arteries. The Table 1 Clinical characteristics of included patients
Variables
Study population (N = 23)
Age ( 
Figure 4
Bradykinin-induced relaxation in human s.c. arteries. (A) Average concentration-response curves for bradykinin in the absence (n = 10) and in the presence of GLP-1 (10 À8 M, n = 10).
(B) Concentration-response curves for bradykinin in the absence (n = 10) and in the presence of liraglutide (10 À8 M, n = 10).
(C) Average concentration-response curves for bradykinin in the absence and in the presence of GLP-1 (10 À8 M) and GLP-1 plus the GLP-1 receptor antagonist, exendin(9-39) (n = 5). The results are means ± SEM. *P < 0.05, significantly different as indicated; twoway ANOVA, followed by Bonferroni post test.
Differing effects of GLP-1 and liraglutide on vascular tone concentrations of GLP-1 and its analogues used in these studies (single addition: 1 nM; concentration-response: 0.1 pM-100 nM) are comparable with plasma concentrations measured after infusion of therapeutic doses of GLP-1 in patients (Toft-Nielsen et al., 1999; Edwards et al., 1998) , ensuring translational results. We therefore suggest that liraglutide induces vasorelaxation in branched mesenteric arteries, whereas GLP-1 and analogues have no direct vasodilating effect in isolated rat and human small resistance arteries without branches.
GLP-1 effects on the vascular nerves
Agonists at GLP-1 receptors have been suggested to increase heart rate by activation of the sympathetic nervous system (Smits et al., 2016) , and therefore, GLP-1 receptor agonists may also regulate vascular tone by interaction with the nerve endings in the vascular wall similar to suggested effects of other gut-derived peptides (Gradin et al., 2006) . This has to our knowledge, not been examined before. EFS is a method that allowed us to activate vascular sympathetic nerve endings in a single isolated vessel. In our experiments, GLP-1 and liraglutide did not reduce the vascular contractions due to EFS and evoked by neurotransmitter release from vascular sympathetic nerves in rat mesenteric arteries. Neither did they increase the responses, suggesting that GLP-1 and liraglutide have no effects on the vascular sympathetic nervous activity in rat mesenteric arteries.
GLP-1 effect on endothelium-dependent relaxation
A possible GLP-1 effect on endothelium-dependent relaxation at normoglycaemic conditions was examined in both rat mesenteric and s.c. arteries from patients with arterial
Figure 5 GLP-1 potentiates ACh-induced relaxation in rat mesenteric arteries kept in high glucose. Concentration-response curves for ACh in rat meseneric arteries without branches kept (A) at 5.5 mM (n = 13) and 40 mM (n = 15) glucose, (B) at 40 mM glucose in the absence (n = 11) and in the presence of GLP-1 (10 À8 M, n = 12), (C) at 40 mM glucose in the presence of GLP-1 (10 À8 M) without (n = 11) and with (n = 4) exendin-(9-39), (D) at 40 mM glucose in the absence (n = 9) and in the presence of liraglutide (10 À8 M, n = 10), (E) at 40 mM glucose in the absence (n = 10) and in the presence of GLP-1(9-36) (10 À8 M, n = 5) and (F) at 40 mM glucose in the absence (n = 10) and in the presence of the SOD mimetic, tempol (10 À4 M, n = 10), and at 5.5 mM glucose (n = 10). Results are means ± SEM. *P < 0.05, significantly different as indicated; two-way ANOVA, followed by Bonferroni post test.
disease. Previous studies in patients have shown apparently conflicting results about a possible GLP-1 effect on vascular endothelial function. In contrast to healthy subjects, infusion of GLP-1 increased forearm blood flow in patients with T2D (Nystrom et al., 2004) , and the GLP-1 receptor agonist exenatide potentiated ACh vasodilatation in adipose tissue arterioles (Koska et al., 2010) . Others found no effect of the GLP-1 receptor agonist liraglutide on endotheliumdependent vasodilatation in T2D patients (Nandy et al., 2014) . As the human arteries used in this study were obtained from patients with arterial disease, they may have some degree of endothelial dysfunction. In contrast to liraglutide, GLP-1 induced a small leftward shift of the concentration-response curves for bradykinin in the human s.c. arteries. Previous studies have shown that exendin-4 potentiates ACh vasodilatation in human adipose arterioles by a GLP-1 receptor-dependent mechanism (Koska et al., 2010) . However, in the present study, the effect of GLP-1 on bradykinin relaxation persisted in the presence of exendin(9-39) suggesting the effect was independent of GLP-1 receptors. Taken together, our findings suggest that different mechanisms are involved in the effect of, respectively, GLP-1 and GLP-1 analogues on endothelial function in human arteries. As GLP-1 did not seem to have any effects at normoglycaemic conditions in rat mesenteric arteries, it was interesting to examine if a hyperglycaemic condition comparable with the state of hyperglycaemia in diabetic patients is required for GLP-1 to mediate its actions. Previous studies found that the GLP-1 receptor agonist exendin-4 improved endothelium-dependent relaxation in vessel exposed to high glucose (Salheen et al., 2015; Koska et al., 2015) . We found that exposure of rat mesenteric arteries to high glucose impaired relaxation to ACh and that native GLP-1 almost reversed this high glucose-induced damage. As ACh relaxation is dependent on endothelial function, our results suggest that GLP-1 improves endothelial function in vessels that have been exposed to hyperglycaemia, consistent with the findings by Salheen et al. (2015) and Koska et al. (2015) . A GLP-1 concentration of 10 nM was required to significantly increase the potency of ACh (Supporting Information Figure S4 ), a concentration similar to the plasma concentrations measured after s.c. injection of therapeutic concentrations of liraglutide (Danne et al., 2017; Damholt et al., 2006) . Liraglutide or the cleaved metabolite of GLP-1, GLP-1(9-36), did not reproduce the effect of GLP-1. This can be due to differences in chemical structure of GLP-1 and liraglutide (Lund et al., 2014) . Nevertheless, we found an effect of GLP-1 on hyperglycaemia-induced impairment of endotheliumdependent relaxation, but as we were not able to show a similar effect of liraglutide, it is uncertain if this is the major mechanism resulting in the lowering of BP in diabetic patients treated with GLP-1 analogues. Furthermore, it is noteworthy that GLP-1 plasma levels have been found to be associated with BP in normoglycaemic young healthy adults as well (Krisai et al., 2015) , demonstrating that there may be other GLP-1 effects of importance that affect BP.
Exendin(9-39) did not attenuate the effect of GLP-1 suggesting that the effect is independent of GLP-1 receptors. These data conflict with the results of Salheen et al. (2015) , indicating that further studies are needed to clarify the possible independence or dependence on GLP-1 receptors. However, previous investigations have suggested that exendin-4 and the DPP-4 inhibitor, linagliptin, potentiate ACh relaxations in rat mesenteric arteries exposed to high glucose by a mechanism decreasing vascular superoxide levels (Salheen et al., 2015) . Also, native GLP-1 decreased monocyte-derived oxidative stress (Steven et al., 2017) . In the present study, a SOD mimetic, tempol, leftward-shifted the concentration-response curves for ACh in arteries exposed to high glucose, suggesting vascular superoxide levels played a role in high glucose impairment of ACh relaxation. Moreover, we found that GLP-1 prevented impairment of ACh relaxation by the superoxide generator pyrogallol, while this was not the case for liraglutide. Finally, measurements of vascular superoxide levels by use of dihydroethium revealed that GLP-1 markedly decreased the levels. Our results suggest that one vascular action of therapeutic concentrations of native Figure 6 GLP-1 potentiates ACh-induced relaxation in rat mesenteric arteries exposed to the superoxide generator, pyrogallol. Concentration-response curves for ACh in rat mesenteric arteries without branches exposed to the superoxide generator, pyrogallol (3 × 10 À5 M) (A) in the absence (n = 10) and in the presence of GLP-1 (10 À8 M, n = 10) or (B) in the absence (n = 10) and in the presence of liraglutide (10 À8 M, n = 10). The experiments were performed in the presence of indomethacin (10 À6 M). Results are means ± SEM. *P < 0.05, significantly different as indicated; two-way ANOVA followed by Bonferroni post test.
Differing effects of GLP-1 and liraglutide on vascular tone means (n = 9) ± SEM. *P < 0.05, significantly different from 5 mM glucose; # P < 0.05, significantly different from 40 mM glucose-exposed vessels; one-way ANOVA followed by Tukey's multiple comparisons test.
GLP-1, but not of liraglutide or GLP-1(9-36), is that it improves endothelium-dependent relaxation at a high glucose concentration, possibly by a pathway which is independent of GLP-1 receptors but involving inhibition of vascular superoxide levels. In summary, our data suggest that, in normoglycaemic conditions, a mechanism dependent on GLP-1 receptors was involved in liraglutide relaxation in branched arteries, while GLP-1 and its analogues, at therapeutic concentrations, have no direct vasodilating effect on the smooth muscle cells in arterial segments without branches and no pre-junctional effect on the neurotransmitter release from the sympathetic vascular nerves. We also found that inhibition of vascular superoxide levels contributed to the GLP-1 receptor-independent potentiation of endotheliumdependent vasodilatation in hyperglycaemic conditions. The latter mechanism may play a role in GLP-1-induced leftward-shift of concentration relaxation curves for bradykinin in s.c. arteries from patients with peripheral arterial disease. These studies suggest that different mechanisms are involved in GLP-1-induced and liraglutide-induced vasodilatation in small arteries and may contribute to the BP-lowering effect of GLP-1 analogues, as previously observed in treatment of patients with Type 2 diabetes. Toft-Nielsen MB, Madsbad S, Holst JJ (1999 
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https://doi.org/10.1111/bph.14534( Figure S1 Average effect of single concentrations of GLP-1 (0.1-1 nM) on phenylephrine contracted vessels and the effect of GLP-1 (10 À8 M) in the absence and the presence of linagliptin (10 À6 M) in rat mesenteric arteries. Figure S2 Lack of effect of native GLP-1 and liraglutide on maximum peak of neurogenic contractions in rat mesenteric arteries. Figure S3 Bradykinin induced relaxation in human subcutaneous arteries from patients without (non-DM) and with diabetes mellitus (DM). Figure S4 Average effect of single concentrations of GLP-1 (0.1-10 nM) on phenylephrine contracted vessels and acetylcholine relaxation in arteries kept in physiological saline solution with high glucose (40 mM). Figure S5 Average effect of single concentration of linagliptin on acetylcholine relaxation in phenylephrinecontracted vessels exposed to either (A) high glucose or (B) the superoxide generator, pyrogallol.
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